FDA Grants Priority Review for Roche's Tecentriq for a Certain Type of Stage III Colon Cancer
June 12, 2026
June 12, 2026
BASEL, Switzerland, June 12 (TNSjou) -- Roche, a biotech company, issued the following news release on June 11, 2026:
* * *
FDA grants Priority Review for Roche's Tecentriq for a certain type of stage III colon cancer
* Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone/1
* Nearly one in three patients with stage III colon c . . .
* * *
FDA grants Priority Review for Roche's Tecentriq for a certain type of stage III colon cancer
* Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone/1
* Nearly one in three patients with stage III colon c . . .